Oric Pharmaceuticals Inc (ORIC) News

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

Form D - Notice of Exempt Offering of Securities

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

ORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding Update

Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b clinical study...

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking...

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Announced focused registrational clinical development plans for lead programs, extended cash runway, and...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...